Biogen Inc (NASDAQ:BIIB) is a global biotechnology company focused on the discovery, development and delivery of therapies for the treatment of neurological and neurodegenerative diseases. The company’s core business encompasses research in multiple sclerosis, spinal muscular atrophy, amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. Its portfolio includes several market-leading products such as Tecfidera and Tysabri for multiple sclerosis, Spinraza for spinal muscular atrophy, and Fumaderm for psoriasis. Biogen also actively advances research in next-generation gene therapies and antibody-based treatments, leveraging its expertise in molecular biology, translational medicine and innovative drug delivery platforms.
Founded in 1978 by a group of visionary scientists in Geneva, Switzerland, Biogen established itself early on as a pioneer in recombinant DNA technology. The company maintains its global headquarters in Cambridge, Massachusetts, and operates research and development facilities in the United States, Europe and Asia. Its commercial footprint spans nearly 90 countries, with significant market presence in North America, Europe, Japan and key emerging markets. Over the years, Biogen has pursued strategic collaborations and licensing agreements with academic institutions, biotechnology startups and larger pharmaceutical companies to expand its pipeline and optimize global distribution channels.
Led by Chief Executive Officer Michel Vounatsos, Biogen’s executive team brings together seasoned leaders from the biotechnology and pharmaceutical sectors, underpinned by a strong commitment to research excellence and patient-centric innovation. The company emphasizes disciplined capital allocation, operational efficiency and strategic partnerships to accelerate the development of transformative therapies. Beyond its scientific endeavors, Biogen has established corporate responsibility initiatives focused on access to healthcare, environmental sustainability and community engagement, reflecting its mission to improve the lives of patients around the world.
AI Generated. May Contain Errors.